| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Semaglutide |
| Brand | Ozempic® |
| Indication | For the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise/as monotherapy when metformin is considered inappropriate due to intolerance or contraindications/in addition to other medicinal products for the treatment of diabetes |
| Assessment Process | |
| Rapid review commissioned | 12/03/2018 |
| Rapid review completed | 10/04/2018 |
| Rapid review outcome | A full pharmacoeconomic assessment is recommended on the basis of the proposed price, relative to currently available therapies. |
The HSE has approved reimbursement September 2018.
